TROG 16.01 (NIVORAD)

Primary sponsor: The University of Sydney
Collaborating groups: Australasian Lung Cancer Trials Group (ALTG) and Trans Tasman Radiation Oncology Group (TROG)

Title

A randomised phase II trial of nivolumab and stereotactic ablative body radiotherapy in advanced non-small cell lung cancer, progressing after first or second line chemotherapy.

Summary

The aim of this study is to determine the activity and safety of treating an asymptomatic, extrapulmonary metastasis with a single fraction of SABR, during immunotherapy with nivolumab in advanced NSCLC progressing after 1 or 2 lines of chemotherapy.

Final Accrual

Trial Status

Closed to follow up

Date of accrual completion

30th June 2019

Trial chairperson

A/Prof Paul Mitchell, Austin Health, VIC
TROG Chair: Dr Shankar Siva, Peter MacCallum Cancer Centre, VIC

Trial contact

NIVORAD Trial Coordinator ​
Phone: 02 9562 5000
Email: nivorad@ctc.usyd.edu.au 

Further information

TROG trial 16.01 on Australian Cancer Trials website

Trial resources for TROG members

TROG 16.01 member page